Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$9.57 USD
+0.07 (0.74%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.58 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Brokerage Reports
Amicus Therapeutics, Inc. [FOLD]
Reports for Purchase
Showing records 101 - 120 ( 170 total )
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Recap; Galafold, AT-GAA, and Beyond; Target Increased to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post Investor Day: Lots to Like Over a 12+ Month Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Maturing AT-GAA Pompe Data Reinforce the Dream
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1H19 Recap: Execution Across the Burgeoning Pipeline Is the Theme
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CLN6 Gene Therapy Changes the Course of Another Scourge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Previewing 2Q19; Expectations Around Galafold and Beyond
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Democratization of AAV Availability Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Amicus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We initiate on Amicus with a Buy rating and $18 target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D